Home › Funds › Defilade Capital Management, L.P. › OLMA
Defilade Capital Management, L.P. position in OLMA
OLEMA PHARMACEUTICALS INC · Health Care
Defilade Capital Management, L.P. reported holding 924,758 shares of OLMA (OLEMA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$11.6M, representing 1.55% of its reported portfolio and ranking #25 among its reported holdings. Defilade Capital Management, L.P. has disclosed OLMA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s OLMA position evolved
Defilade Capital Management, L.P. first disclosed a stake in OLMA in Q4 2025 at 1,234,634 shares (US$30.9M). Across 3 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 924,758 shares valued at US$11.6M — a reduction of -579,778 shares quarter over quarter.. Notable position changes include a 39% trim in Q2 2026 (shares fell 31% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.23M | $30.87M | New |
| Q1 2026 | 1.50M | $22.43M | Add |
| Q2 2026 | 924.76K | $11.57M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OLMA and 13F data
OLMA (OLEMA PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in OLMA — the largest reported positions include Paradigm Biocapital Advisors LP (US$108.5M), Bain Capital Life Sciences Investors, LLC (US$88.6M), BVF INC/IL (US$66.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OLMA
- Paradigm Biocapital Advisors LP 8.67M sh · $108.47M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 7.09M sh · $88.64M · Q2 2026
- BVF INC/IL 5.30M sh · $66.25M · Q2 2026
- Siren, L.L.C. 4.86M sh · $60.76M · Q2 2026
- Logos Global Management LP 3.21M sh · $40.14M · Q2 2026
- Cormorant Asset Management, LP 2.15M sh · $26.90M · Q2 2026
- Lightspeed Management Company, L.L.C. 1.36M sh · $16.95M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 1.20M sh · $15.01M · Q2 2026
- Vivo Capital, LLC 671.84K sh · $8.40M · Q2 2026
- Jones Hill Capital LP 574.17K sh · $7.18M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held OLMA?
Defilade Capital Management, L.P. has disclosed OLMA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Defilade Capital Management, L.P.'s current position in OLMA?
As of Q2 2026, Defilade Capital Management, L.P. holds 924.76K shares of OLMA (OLEMA PHARMACEUTICALS INC), valued at $11.57M, representing 1.55% of its reported portfolio and ranking #25.
Has Defilade Capital Management, L.P. been buying or selling OLMA?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. reduced its position in OLMA.
Which other funds hold OLMA?
Other major institutional holders of OLMA include Paradigm Biocapital Advisors LP, Bain Capital Life Sciences Investors, LLC, BVF INC/IL, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.